Your browser doesn't support javascript.
loading
Changes in the multidisciplinary management of rectal cancer from 2009 to 2015 and associated improvements in short-term outcomes.
Roxburgh, C S D; Strombom, P; Lynn, P; Cercek, A; Gonen, M; Smith, J J; Temple, L K F; Nash, G M; Guillem, J G; Paty, P B; Shia, J; Vakiani, E; Yaeger, R; Stadler, Z K; Segal, N H; Reidy, D; Varghese, A; Wu, A J; Crane, C H; Gollub, M J; Saltz, L B; Garcia-Aguilar, J; Weiser, M R.
Afiliação
  • Roxburgh CSD; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Strombom P; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
  • Lynn P; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Cercek A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Gonen M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Smith JJ; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Temple LKF; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Nash GM; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Guillem JG; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Paty PB; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Shia J; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Vakiani E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Yaeger R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Stadler ZK; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Segal NH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Reidy D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Varghese A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Wu AJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Crane CH; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Gollub MJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Saltz LB; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Garcia-Aguilar J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Weiser MR; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Colorectal Dis ; 21(10): 1140-1150, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31108012
ABSTRACT

AIM:

Significant recent changes in management of locally advanced rectal cancer (LARC) include preoperative staging, use of extended neoadjuvant therapies and minimally invasive surgery (MIS). This study was aimed at characterizing these changes and associated short-term outcomes.

METHOD:

We retrospectively analysed treatment and outcome data from patients with T3/4 or N+ LARC ≤ 15 cm from the anal verge who were evaluated at a comprehensive cancer centre in 2009-2015.

RESULTS:

In total, 798 patients were identified and grouped into five cohorts based on treatment year 2009-2010, 2011, 2012, 2013 and 2014-2015. Temporal changes included increased reliance on MRI staging, from 57% in 2009-2010 to 98% in 2014-2015 (P < 0.001); increased use of total neoadjuvant therapy, from 17% to 76% (P < 0.001); and increased use of MIS, from 33% to 70% (P < 0.001). Concurrently, median hospital stay decreased (from 7 to 5 days; P < 0.001), as did the rates of Grade III-V complications (from 13% to 7%; P < 0.05), surgical site infections (from 24% to 8%; P < 0.001), anastomotic leak (from 11% to 3%; P < 0.05) and positive circumferential resection margin (from 9% to 4%; P < 0.05). TNM downstaging increased from 62% to 74% (P = 0.002).

CONCLUSION:

Shifts toward MRI-based staging, total neoadjuvant therapy and MIS occurred between 2009 and 2015. Over the same period, treatment responses improved, and lengths of stay and the incidence of complications decreased.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Neoplasias Retais / Gerenciamento Clínico / Terapia Neoadjuvante / Protectomia Tipo de estudo: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Equipe de Assistência ao Paciente / Neoplasias Retais / Gerenciamento Clínico / Terapia Neoadjuvante / Protectomia Tipo de estudo: Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article